TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Evolan Pharma AB
Closing information (x1000 NOK)
Closing information | 2022/12 | 2021/12 | 2020/12 |
Turnover | 697,061 | 652,113 | 569,279 |
Financial expenses | 1,668 | 1,316 | 3,735 |
Earnings before taxes | 221,228 | 190,100 | 127,830 |
EBITDA | 290,042 | 258,460 | 199,343 |
Total assets | 816,768 | 538,601 | 440,597 |
Current assets | 465,538 | 345,072 | 261,774 |
Current liabilities | 202,186 | 149,274 | 157,598 |
Equity capital | 498,965 | 356,677 | 238,062 |
- share capital | 95 | 98 | 105 |
Employees (average) | 27 | 27 | 27 |
Financial ratios
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Solvency | 61.1% | 66.2% | 54.0% |
Turnover per employee | 25,817 | 24,152 | 21,084 |
Profit as a percentage of turnover | 31.7% | 29.2% | 22.5% |
Return on assets (ROA) | 27.3% | 35.5% | 29.9% |
Current ratio | 230.3% | 231.2% | 166.1% |
Return on equity (ROE) | 44.3% | 53.3% | 53.7% |
Change turnover | 64,547 | 122,165 | 107,888 |
Change turnover % | 10% | 23% | 23% |
Chg. No. of employees | 0 | 0 | 1 |
Chg. No. of employees % | 0% | 0% | 4% |
Total value of public sale
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.